One of the major hurdles in the development of safe and effective drugs targeting G-protein coupled receptors (GPCRs) is finding ligands that are highly selective for a specific receptor subtype. Structural understanding of subtype-specific binding pocket variations and ligandereceptor interactions may greatly facilitate design of selective ligands. To gain insights into the structural basis of ligand subtype selectivity within the family of adenosine receptors (AR: A 1 , A 2A , A 2B , and A 3 ) we generated 3D models of all four subtypes using the recently determined crystal structure of the A A2 AR as a template, and employing the methodology of ligand-guided receptor optimization for refinement. This approach produced 3D conformational models of AR subtypes that effectively explain binding modes and subtype selectivity for a diverse set of known AR antagonists. Analysis of the subtype-specific ligandereceptor interactions allowed identification of the major determinants of ligand selectivity, which may facilitate discovery of more efficient drug candidates.
Introduction
Major targets for drug discovery and development, proteins of the G-protein coupled receptor (GPCR) family are involved in recognition of a great variety of extracellular signals including ions, small molecules, peptides and globular proteins (Tyndall and Sandilya, 2005; Lagerstrom and Schioth, 2008) . Despite the diversity of natural GPCR ligands, there exist several receptor subfamilies in which all proteins respond to a single endogenous agonist: for example, all GPCRs in the adrenergic subfamily are activated by epinephrine while all muscarinic receptors naturally bind acetylcholine and its derivatives. GPCR subtypes within a subfamily usually have distinct amino acid sequences, tissue distributions, effector coupling, and/or functional and pharmacological profiles; however, their ligand binding pockets are highly conserved within the subfamily. The similarity of the orthosteric binding pockets poses a challenge for design of subtype selective ligands which remains one of the main hurdles in development of safe and effective medications targeting GPCRs.
The Adenosine Receptor (AR) subfamily is comprised of four member subtypes (A 1 , A 2A , A 2B , A 3 ) that present a prominent example of closely related GPCRs activated by a single endogenous agonist, adenosine (Jacobson, 2009 ). All four AR subtypes have been considered as potential therapies for neurodegenerative (Morelli et al., 2009; Sebastiao and Ribeiro, 2009) , cardiac Headrick and Lasley, 2009) , immune, and inflammatory disorders Blackburn et al., 2009 ) and cancer (Fishman et al., 2009) . Functional importance of different AR subtypes in various body functions and tissues imposes very high requirements on subtype selectivity of AR antagonists and agonists as candidate drugs (Yan et al., 2003; Jacobson and Gao, 2006) and leads to significant challenges in clinical development of the candidate drugs. Despite early setbacks, 2008 has been marked by successful FDA approval of the new generation A 2A AR selective agonist regadenoson as a coronary vasodilator for use in myocardial perfusion imaging (Thomas et al., 2009 ). This breakthrough, along with other advances in preclinical and clinical studies (Jacobson, 2009 ) boosts interest to development of a new generation of bioavailable and safe agonists and antagonists for adenosine receptors.
The recent crystal structure of A A2 AR in complex with an antagonist (PDB code: 3EML) (Jaakola et al., 2008) elucidates the details of ligandereceptor interactions at atomic resolution (Fig. 1) , and provides an excellent template for virtual ligand screening and structure-based drug discovery. This was recently demonstrated by exceptionally high hit rates (w40%) in prospective virtual ligand screening (VLS) for novel chemotypes of AA2AR antagonists (Katritch et al., 2010a; Carlsson et al., 2010) . The core ligandereceptor interactions are defined by aromatic stacking of the ligand aromatic ring system with the side chain of Phe168 (5.29), hydrophobic interactions with Leu249(6.51), Ile274(7.39) and M177(5.38), and the hydrogen bonding to Asn253(6.55). (Residue numbering is for SWISSPROT human A A2 AR sequence P29274, while BallesteroseWeinstein numbering (Ballesteros and Weinstein, 1995) in parenthesis represents position of the residue relative to the most conserved position in each TM helix, extended to loop regions as in ref Jaakola et al. (2008) . As shown by mutations and computational analysis (Jaakola et al., 2010) , these residues make a major contribution to the ligand binding affinity. Note that the above mentioned "core" pocket side chains are fully conserved in all four AR subtypes, with the exception of Leu replaced by a similar Val side chain in position 6.51 of A 2B . Moreover, there are only a few side chains in the binding pocket of crystallographic antagonist ZM241385, which are conserved in less than 3 subtypes (positions 5.28, 6.66 7.32 and 7.35) , all of them located in the extracellular loop (ECL) region.
The subfamily-wide conservation of the core pocket residues and the peripheral location of non-conserved amino-acids apparently pose serious challenges for the discovery of subtype selective ligands. Previous SAR studies for major AR-binding chemotypes, including xanthine and adenine derivatives and other polyheterocyclic compounds (for example reviewed in ref Cristalli et al., 2008) , suggest that the core chemical scaffolds themselves do not provide significant subtype selectivity. Extensive SAR analysis of multipoint substitutions in the scaffolds, in some cases guided by pharmacophore models, was required to achieve high affinity and reliable selectivity for each of the subtypes. Our virtual ligand screening efforts against the A A2 AR crystal structure (Katritch et al., 2010a ) also suggest that ligand subtype selectivity, especially between A 2A , A 2B and A 1 subtypes, does not come automatically with the high affinity binding to one of the subtypes. Indeed, while most of novel A 2A binders found in the above VLS study among commercially available compounds had reduced affinity to A3 subtype, only one of them showed w10-fold selectivity vs. A 1 subtype.
In the past 20 years, intensive drug discovery efforts have resulted in hundreds of SAR profiles and yielded a number of AR ligands with respectable (w100 fold) selectivity for each of the subtypes (Jacobson and Gao, 2006) . However, there is an ongoing interest in new chemical scaffolds and new highly selective compounds with improved pharmacological properties. As there is still no clear understanding of structural basis of ligand selectivity in ARs, structural models of AR subtypes that may explain and predict ligand selectivity are of paramount importance for rational drug discovery.
In this study we set out to generate accurate 3D models of all four AR subtypes that successfully predict the subtype selectivity of known antagonists. We used the crystal structure of A A2 AR as a 3D template, and refined the models with a set of known subtypeselective ligands (Fig. SM2 ) using the recently developed Ligand Guided Receptor Optimization approach (Cavasotto et al., 2008; Reynolds et al., 2009) . While the starting raw homology models showed poor discrimination between ligands and decoys in our VLS benchmarks, the performance of the optimized models improved dramatically through iterations of the procedure. For A 1 and A 3 subtypes, the screening performance approached that of the A A2 AR crystal structure. We then built the "virtual selectivity panel" that demonstrated the excellent discrimination between subtypeselective ligands. We also suggested the structural features of AR subtypes that play the key roles in selective ligand recognition. The developed selectivity panel can be applied to rational design of novel subtype-selective AR antagonists. With the rapid progress of GPCR crystallography, the approach will become applicable to other GPCR families with at least one representative crystal structure and known high affinity ligands.
Methods

Subtype selective ligand sets
High affinity adenosine receptor antagonists with at least 50-fold selectivity for each of the AR subtypes were collected from literature (see Supplementary Materials). The ligand set includes preclinical and clinical candidates listed in a recent review (Jacobson and Gao, 2006) , a diverse set of A 2A AR selective compounds from ref (Mantri et al., 2008) (Jaakola et al., 2008) , based on BallesteroseWeinstein GPCR numbering) (Ballesteros and Weinstein, 1995) . Side chain carbons are colored according to their conservation: green e fully identical in all 4 subtypes, cyan e in 3 subtypes, yellow e in 2 subtypes, orange e in only one subtype. Binding pocket residue alignment (B) uses the same color coding. Residues that vary between clinically relevant species (human, rat, mouse, dog) in the same subtype are marked with a red box (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
for which full AR selectivity profiles were available. The ligand set included 22 selective compounds for each of the four subtypes, 88 compounds total.
A set of 1000 decoy compounds was randomly selected from a Chemdiv Inc. database of drug-like compounds so that distributions of chemical properties (molecular weight and predicted LogP and LogS values) of ligand and decoy sets were similar.
Homology modeling of A 1 , A 2B and A 3 adenosine receptor subtypes
The initial homology models of A 1 AR, A 2B AR and A 3 AR were generated using ICM homology modeling tool with extensive side chain sampling and refinement Cardozo et al., 2000) . For stretches of residues that aligned against gaps in the A A2 AR template, the algorithm used an automated search for initial loop placement. The portion of the loop EL2 between positions Leu141(4.62) and Cys166(5.27) was omitted. For short loop EL3, extensive conformational modeling was performed using ICM global optimization algorithm, which included sampling of backbone conformations .
Ligand guided optimization of AR subtype models
Initial models were optimized using Ligand-guided Receptor Optimization algorithm (LiBERO) described previously (Katritch et al., 2010a) . Briefly, the protocol consists of repeated steps of model conformational sampling and selection based on their VLS screening performance evaluated on a small compound benchmark. The version of the LiBERO algorithm employed in this paper did not use large scale sampling of the protein backbone. At each step of the optimization procedure, a set of 100 conformational models was generated for each adenosine receptor subtype by co-optimization of representative subtype-selective antagonists in the model binding pocket. The optimization was performed using BPMC method , which allowed extensive sampling of the flexible ligand and flexible receptor side chain conformations, while limiting protein backbone movements using harmonic restraints. For each of the resulting conformers, a small-scale VLS benchmarking was performed and the model screening performance was quantified using the NSQ_AUC measure described below.
ICM grid docking
ICM molecular modeling software ) was used for ligand docking and scoring. ICM ligand docking is based on biased probability Monte Carlo (BPMC) optimization of the ligand internal coordinates in the set of grid potential maps of the receptor . Compounds in twodimensional representation were converted to 3D and optimized using MMFF-94 force field (Halgren, 1995) . The generated conformers were then placed into the binding pocket in four principal orientations and used as starting points for Monte Carlo optimization. The optimized energy function included the ligand internal strain and a weighted sum of the grid map values in ligand atom centers. To ensure convergence of the Monte Carlo optimization, three independent runs of the docking procedure were performed, and the best scoring pose per compound was kept. No distance restraints or any other experimentally derived information was used in the ligand docking procedure. The docking procedure took about 30 seconds of Intel Xeon 2.8 Ghz CPU time per compound, and was performed using a 100 processor Linux cluster.
ICM full-atom scoring
The top-scoring ligand poses were merged with their receptors to obtain fullatom models of the complexes. The models were evaluated with all-atom ICM ligand binding score (Bursulaya et al., 2003; Schapira et al., 1999 ) that has been previously derived from a multi-receptor screening benchmark as a compromise between approximated Gibbs free energy of binding and numerical errors. The score was calculated as:
where E vw , E el , E hb , E hp , and E sf are Van der Waals, electrostatic, hydrogen bonding, non-polar and polar atom solvation energy differences between bound and unbound states, E int is the ligand internal strain, DS Tor is its conformational entropy loss upon binding, T ¼ 300 K, and a i are ligand-and receptor-independent constants.
2.6. Evaluation of the model screening performance using normalized square-root AUC Benchmark compounds were docked into each model and ranked by their fullatom score. To build the compound recognition curve, for each compound rank i, the fraction of true positive among i top-scoring compounds in the list was plotted against Sqrt(i)/n, where n is the number of false positive compounds in the list. The area under curve was calculated and normalized to the range of 0e100 to obtain the Normalized Square Root Area Under Curve, or NSQ_AUC. Calculated as described, NSQ_AUC mildly emphasizes the initial enrichment in small molecule screening which makes it a suitable objective function for pocket optimization (Katritch et al., 2010b) .
Results and discussion
Docking and virtual ligand screening for A 2A subtype identifies core ligandepocket interactions
We first evaluated the ability of the A 2A AR crystal structurebased models (Jaakola et al., 2008) to accommodate known A 2A AR specific antagonists and recognize them in a set of random druglike decoys. A benchmark compound set included 22 selective A 2A AR antagonists and 1000 decoys (see Methods section). In Fig. 2A , the predicted binding poses are shown for seven A 2A antagonists that were found among 12 highest-scoring compounds, as well as for compound #8 (CSC (Jacobson and Gao, 2006) ), which is the highest scoring xanthine-like compound.
The predicted docking poses for known A 2A AR-selective antagonists suggest that these chemically diverse compounds bind similarly to the ZM241385 antagonist in the published crystal structure (Jaakola et al., 2008) . The common core interaction for all ligands involves aromatic stacking with the conserved Phe168 (5.29) of the receptor and additional hydrophobic interactions with the conserved Ile274(7.39) and Leu249(6.51) side chains. Strong polar interactions are formed with the side-chain of the conserved Asn253(6.55), where the role of the hydrogen bond donor in most high-affinity ligands is played by the exocyclic amine group, with a notable exception of methylxanthine analogues (e.g. compound #8) that lack this group. The exocyclic amine group also forms a hydrogen bond to Glu169(5.30) side chain in the EL2, which is present in subtypes A 2A , A 2B and A 1 , but replaced by Val in the A 3 AR. Most of the A2A ligands also have an acceptor for H-bonding with Asn253(6.55) amide donor. This interaction pattern is consistent with the previous mutation data summarized in ref (Kim et al., 2003; Cristalli et al., 2008) showing loss of affinity for Asn253 (6.55) and Ile274(7.39) mutants, as well as with recent mutagenesis data (Jaakola et al., 2010) showing the critical role of Phe168(5.29) and Leu249(6.51) for both agonist and antagonist binding.
The results of benchmark screening with the A 2A AR crystal structure model, illustrated in Fig. 2B ,C shows very favorable binding scores for most A 2A AR antagonists and high efficiency of the model in separating those antagonists from decoy compounds. As mentioned above, seven out of twelve top-ranking compounds are A 2A AR antagonists. Only 6 out of 22 A 2A AR ligands in the set were not predicted as A 2A AR ligands based on their ICM binding score >À32.0 kJ/mol, including two xanthine analogues and two other compounds lacking the exocyclic amine.
Initial modeling of A 1 , A 2B , and A 3 adenosine receptor subtypes
The initial models of AR subtypes A 1 , A 2B , and A 3 were generated with standard homology modeling tools using sequence alignments shown in Fig. SM1 . The alignment demonstrates the high variability of the EL2 part between residues Leu141(4.62) and Cys166(5.27). The length and the disulfide bonding patterns in this region differ between the AR subtypes; moreover, this region is partially disordered in A 2A AR crystal structure. Because this ambiguous portion of the EL2 is located far from the binding pocket and is unlikely to make a significant contribution to orthosteric ligand binding, it was excluded from the models. In contrast, the short extracellular loop EL3, ranging from 9 amino acid length in A 2B AR to just 5 amino acids in A 3 AR, can be involved in subtypespecific binding properties, at least indirectly via a hydrogen bonding network with the side-chain of E169(5.30), as seen in the crystal structure (Jaakola et al., 2008) . To account for possible effects of EL3, the conformation of EL3 backbone and side chains was predicted using ICM global optimization algorithm. The standard homology building procedure also included the initial refinement of the modified side chains through their global energy optimization (Cardozo et al., 1995) .
The initial models were tested for their ability to discriminate between known subtype-selective compounds and decoys in the ligand benchmark (see Materials and Methods). The initial A2A model derived from the high-resolution crystal structure, demonstrated high compound recognition with AUC of 90% (NSQ_AUC ¼ 75). In stark contrast to A 2A , the initial models of other subtypes had very poor performance. In particular, the model of the most distant subtype, A 3 , had a pronounced negative selectivity (NSQ_AUC ¼ À11), suggesting some steric hindrance for ligand binding. Our analysis showed that this hindrance was associated with a specific rotamer state of the Val(5.30) side chain in the initial model.
Ligand-guided optimization of adenosine receptor subtype models
The initial models of the AR subtypes were subsequently optimized using an automated LiBERO algorithm as described previously for A 2A AR (Katritch et al., 2010a) , see Methods. In each iteration step of the procedure, at least 100 distinct conformations of the binding pocket were generated with a stochastic sampling procedure (see Methods). The performance of each conformational model in separating the subtype selective ligands from decoy compounds was assessed by calculating ROC curves and corresponding values of linear AUC (ROC_AUC), normalized square root AUC (NSQ_AUC) and initial enrichment factors (EF1%). Fig. 3 presents the results of the optimization procedure for A 1 , A 3 and A 2B adenosine receptor subtypes. For the A2A optimization, which started with the high-performing crystal structure model, the procedure did not affect the ROC_AUC value and only modestly improved NSQ_AUC and initial enrichment EF(1%) after two optimization steps. In contrast, for A 3 , a change of the Val5.30 rotamer in the first iteration models led to a dramatic rise in the screening performance. The iterative improvement of VLS performance for A 1 and A 2B subtypes was more gradual, suggesting more complicated adjustments in the binding pocket involving multiple side chain movements and minor backbone adjustments. After four iterations sampling the total of 400 binding pocket conformations the screening performance apparently reached a plateau for all AR subtypes. The best optimized models represented by red ROC curves in Fig. 3 show reasonable performance for A 1 and A 3 subtype screening models, which is on par with the X-ray-based A 2A model. The lower performance of the A 2B model may be explained by the fact that the A 2B selective ligand set was comprised of xanthine derivatives that generally have less favorable scores in screening benchmarks (compare compound 8 in Fig. 2) .
Note, that such distinct behavior of the optimization procedure for different AR subtypes reflects not only differences in the receptor structures, but also composition of the corresponding ligand sets, some of which are less diverse than others. For example, most of the A 3 selective ligands in our set are based on the pyrazolo-triazolo-pyrimidine scaffold {Baraldi, 2003 #1728}, and therefore applicability of the optimized A3 model may be limited to this and some similar chemotypes. On the other hand, such singlescaffold optimized models can be especially useful in structure based SAR analysis and lead optimization for this specific scaffold, as they may reflect scaffold-specific induced fit in the binding pocket. One may also find that some of the compounds most dissimilar to the major chemotypes (e.g. mantri_l, mantri_r, veld_3 in our sets), which probably represent alternative binding modes or allosteric sites, and their presence in the training set does not improve the overall model quality. The construction of ligand sets therefore should be guided on practice not only by availability and quality of the ligand binding data, but also by the intended application of the optimized models in a specific drug discovery project.
Subtype selectivity profiles for the optimized AR models
Ligand selectivity profiles were generated by docking a set of all 88 AR ligands from Fig. SM1 into the optimized models A 1 , A 2A , A 2B and A 3 adenosine receptor subtypes. Fig. 4 shows individual selectivity ROC curves for these benchmarks. The ROC curves were calculated for each subtype model and for each subset of selective ligands. For example, the red curve in A 1 model panel of Fig. 4 uses the subset of A 1 selective ligands as "positives" and the other 66 ligands as "negatives". High ROC_AUC and NSQ_AUC values for this curve, shown in bold type, suggest that the optimized A 1 AR model is highly efficient in discriminating selective A 1 antagonists from other adenosine receptor binders.
Analysis of individual curves suggests a specific pattern of selectivity between the individual subtypes. For example, in both A 2A and A 2B panels, the separation between A 2A and A 2B ligand sets (yellow and green curves respectively), though still significant, is the smallest as compared to other subtypes. This is likely to reflect the fact that A 2A and A 2B receptor subtypes have the highest level of sequence conservation, especially in the binding pocket. This "convergence" of selectivity for A 2A and A 2B binding models was observed even despite the fact that ligand set for A2A and A2B (Fig. SM1) are quite dissimilar chemically.
3D models suggest insight into structural basis of ligand subtype selectivity
The optimized models of four human AR subtypes with representative subtype-selective ligands are illustrated by Fig. 5 . Similar to the A 2A AR models, all subtypes share core interactions with residues conserved across ARs, including aromatic stacking with Phe(5.29), hydrophobic interactions with conserved Ile(7.39) and Leu(6.51) side chains and strong hydrogen bonding with Asn(6.55). At the same time, model comparison suggests some subtype specific interactions that may serve as key selectivity determinants for individual AR subtypes.
The A 3 subtype is the most divergent from other ARs, with 10 out of 20 side chains in the ligand binding pocket unique for this subtype. The most important difference is a valine in position 5.30: in all other subtypes this position is occupied by a glutamate that plays an important role in high affinity ligand binding by forming a hydrogen bond with the unsubstituted exocyclic amine. With Val in this position, the A 3 AR loses this interaction and therefore allows bulky amine substitutions protruding towards the extracellular opening of the pocket. As mentioned before, some Val rotamer conformations can also partially block this opening, so conformational optimization is required to adequately represent specific ligand binding in A 3 . Importantly, there are two other mutations deeper in the pocket, H(6.52)S and N(5.42)S, in both cases to the smaller Ser side chain. These substitutions create an additional subpocket in A 3 that can be exploited in the design of selective inhibitors. However, none of the A3 selective ligands in our set seem to take advantage of this sub-pocket, as they have a furan group similar to many other AR ligands.
The A 1 subtype has a much closer homology to A 2A and A 2B subtypes, with only 4 side chain substitutions on the periphery of the binding pocket. The change in one of these positions, from Met (7.35) to a smaller Thr, apparently creates an additional sub-pocket in the loop region. This mutation, combined with slightly shifted conformation of E(5.30) in the optimized A 1 AR model makes possible accommodation of relatively small aliphatic and aromatic substitutions at exocyclic amine, which are characteristic of most A 1 -selective ligands. Interestingly, the shift in E(5.30) positions is absolutely required for binding of N-substituted compounds, but is not directly guided by amino acid differences between A 1 and A 2A pockets. One possible indirect explanation is in the modified EL3 loop, which is one amino acid shorter in A 1 than in A 2A ; this difference may impose modified preferences for the position of His (6.66) side chain which plays a key role in stabilizing E(5.30). Other variations in the extracellular loops of the A 1 sequence, M(5.28)E and L(7.32)S, are not predicted to be involved in binding of known A 1 selective ligands. The engagement of these groups would require ligands that have additional hydrophilic extensions. This limited number of "reachable" mutations may explain why A 1 selectivity is usually much harder to achieve than A 3 selectivity.
The A 2B subtype has only two deviations from A 2A in the proximity of the ligand binding pocket. One of them is H(6.66)N in loop EL3, which leads to less stable conformation of E(5.30) in EL2 and thus reduced importance of an unsubstituted exocyclic amine in the ligands. Indeed, most ligands with A 2B vs. A 2A selectivity are based on chemical scaffolds that lack this amino group. The second residue substitution is L(7.32)K at the extracellular opening of the pocket. In the optimized model of A 2B the basic Lys side chain is posed to interact with the acidic groups of the ligands. Some examples of such groups in known A 2B -selective ligands are oxygen in the carbamoyl-methoxy-phenyl moiety of the antagonists (Stefanachi et al., 2008b) or in sulphonyl moiety (Borrmann et al., 2009) . Interestingly, the same substituted carbamoyl-methoxyphenyl motif was also found to confer A 2B selectivity in agonists based on a different adenine-like scaffold (Baraldi et al., 2007) , which suggests general importance of this interaction for A 2B ligand selectivity.
Conclusions
While high resolution 3D structure of adenosine A 2A receptor represents an excellent template for virtual ligand screening for A 2A antagonists, its utility in discovery and optimization of subtype selective adenosine receptor antagonists has yet to be shown. Our results suggest that AR subtype models directly built by homology with A 2A AR crystal structure do not automatically guarantee recognition of subtype specific ligands and may have poor VLS performance. However, optimization of the models with the ligand-guided receptor optimization (LiBERO) methodology improves their VLS performance to the level comparable to that of the crystal structure. The analysis of the optimized models points to some of the non-conserved residues in the extracellular loop region which serve as determinants of ligand selectivity exploited by previously discovered subtype-selective ligands. The resulting models may serve as 3D selectivity panels to predict subtype selectivity of novel AR antagonists, or as structural templates for direct rational design of novel chemotypes of subtype selective AR ligands. The method can be applied to other families of closely related receptor subtypes, for which new 3D information is emerging from the structural genomics initiatives. The only intrinsic limitation of the technique is availability of quality ligand sets, which ideally have to comprise high affinity and high selectivity compounds, and be sufficiently diverse to avoid model overtraining. Fortunately, such ligand sets can be readily constructed for many clinically relevant GPCR targets, making the methodology applicable to rational structure-based design of subtype selective tools compounds and drug candidates.
